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Abstract
Individuals infected with SARS-CoV-2 have been found to develop a variety of cutaneous symptoms. This
study sought to describe varying cutaneous manifestations of COVID-19 in individuals presenting to an
inpatient healthcare facility. We screened individuals who presented with COVID-19 for skin changes
throughout the illness and administered a survey regarding demographics, medical history, and their
cutaneous findings. Three individuals reported varying skin findings including wheals, petechiae,
ecchymosis, and papules. One individual reported a worsening skin condition, psoriasis, as well as a new
skin condition, seborrheic dermatitis. In conclusion, cutaneous manifestations of patients suffering from
COVID-19 are wide-ranging and worsening skin conditions amongst these patients should be further
investigated.

Categories: Dermatology, Infectious Disease
Keywords: cutaneous symptoms, skin changes, covid and skin, sars-cov-2, covid-19

Introduction
Over the past two years, the world has experienced a rapidly evolving healthcare crisis due to the coronavirus
disease 2019 (COVID-19) pandemic. The disease course is highly variable, ranging from asymptomatic
carriers to pneumonia with significant complications [1]. In addition to this, there have been a number of
cutaneous manifestations associated with the disease that are equally wide-ranging [2-4]. Based on a
previous literature review, the prevalence rate for skin changes during COVID-19 infection is between 4.9
and 20.4% [2]. One of the more prominent dermatological diagnoses is pernio, also known as chilblains [2,3].
Chilblains (pernio) or pseudo-chilblains is characterized as violaceous plaques located on the fingers and
toes resembling frostbite, without significant exposure to cold and most often found in younger cases of
COVID-19 [5,6]. Nevertheless, other presentations have also been recorded including but not limited to
maculopapular rashes, purpura, erythema multiforme, urticarial rashes, and vesicular rashes [7].
An individual’s progression of COVID-19 severity may be related to the appearance of specific skin findings
[3]. For example, the appearance of retiform purpura has a high association with acute respiratory distress
syndrome and thrombotic events [3]. On the other end of the spectrum, most individuals with urticarial or
macular erythema experience no complications [3]. Treatment options for these lesions have primarily been
based on what was previously known about similar lesions presenting without COVID-19 [8]. Although, it
has been hypothesized that treating some of these lesions, such as urticarial rashes may also improve the
survival rate of overall COVID-19 [7].
The pathological mechanism of cutaneous manifestations of COVID-19 has not been well studied. However,
based on current literature, it is known that the SARS CoV-2 initially infects humans through the binding of
spike proteins with the angiotensin-converting enzyme 2 (ACE-2) receptor [9]. The infection then triggers a
cascade of local and systemic inflammatory signals, causing widespread damage to several organ systems,
ranging from the respiratory to nervous systems [9,10]. Furthermore, a review of a gene expression database
has shown that ACE-2 gene expression is higher in human skin keratinocytes and basal cells than in lung
tissue [11,12]. This results in a higher number of the ACE-2 receptors, the SARS-CoV2 entry site, in these
tissues [9]. Since SARS-CoV2 is most widely considered to be transmitted through aerosol or droplets, the
skin is more likely a place for further dissemination of the virus during active infection [13]. Additionally, the
pathogenesis of many skin conditions, including psoriasis, atopic dermatitis, and seborrheic dermatitis, is
based on sustained inflammation [14-16].
In addition to skin manifestations of COVID-19, the dermatological community warrants further
investigation of the effects of COVID-19 on previously diagnosed skin conditions [17,18]. For example, there
have been reports of worsening psoriasis with the onset of COVID-19, unexplained by newly prescribed
medications or medication withdrawal [17]. One patient who was previously diagnosed with psoriasis,
presented with COVID-19, had no medication withdrawal or added new medicines, was found to have
worsening psoriatic lesions that improved with the resolution of the disease [17]. Aside from the previously
mentioned case, other more extensive studies found evidence of worsening skin conditions during the
COVID-19 pandemic [19]. However, there needs to be further examination of the etiology of these changes
in the future [18]. To better understand the treatment and prognostic factors of cutaneous manifestations of
COVID-19 and the management of current skin disease, we must continue to document these cases as they
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present to us in the inpatient and outpatient settings. This study presents four cases of COVID-19 who also
reported cutaneous manifestations of the disease and a case of worsening prior dermatological diagnoses.

Case Presentation
In this study, there were four individuals who tested positive for COVID-19 by polymerase chain reaction
(PCR) who also reported skin changes since symptom onset. They were all seen and interviewed in a single
hospital’s emergency department or inpatient setting. These patients were first screened for skin changes
after testing by PCR had confirmed these patients to be positive for COVID-19. After consenting to be part of
this study, the patients were then asked to complete a brief physician-guided questionnaire that included
basic demographics, medical history, history of their COVID-19 illness, and a subjective report of their skin
findings. This was then followed by an objective examination of the skin findings by a physician while
obtaining photographs of the lesions. Consent was obtained whereby the subjects were guaranteed the right
to withdraw from the study, protect their identity, and remove any personal identifiers within the
photographs taken. The patients’ demographics, social history, COVID-19-related information, medical
history, and cutaneous symptoms are summarized in Tables 1-4.

Demographics and Social History

Case 1

Case 2

Case 3

Case 4

Age (years)

51

52

44

47

Gender

Male

Female

Male

Female

Weight (pound)

360

429

177

233

Height (inch)

72

67

72

62

Body Mass Index (pound/inch2 )

49

67

24

43

Smoking Status

No

No

No

Yes, 13 pack-year

Birth Control

N/A

No

N/A

No

New Medications

No

No

No

Ibuprofen previous night prior to admission

TABLE 1: Demographics and Social History.
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Case 1

Case 2

Case 3

Case 4

Setting of Interview

Emergency Department

Inpatient

Inpatient

Emergency Department

Disposition

Inpatient Admission

Inpatient Admission

Inpatient Admission

Discharged

Hospital Length of Stay

3 days

2 days

3 days

0 Days

COVID-19 PCR Testing Result

Positive

Positive

Positive

Positive

Prior COVID-19 Diagnosis

No

No

No

No

Initial Encounter

COVID-19-Related Questions

Immunization Vaccination Information
Immunization Vaccination

No

Yes

No

Yes

Immunization manufacturer

N/A

Moderna (Spikevax)

N/A

Janssen COVID-19 Vaccine

Immunization dose

None

First dose in early 2021

None

First dose in June 2021

Fever

Yes

No

Yes

Yes

Myalgia

Yes

Yes

No

Yes

Fatigue

Yes

Yes

Yes

Yes

Shortness of Breath

Yes

No

No

Yes

Other

Chills

Dizziness

Nausea/Vomiting

Eye redness, dizziness

COVID-19 related Symptoms

TABLE 2: COVID-19-Related Questions.
PCR: polymerase chain reaction
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Medical History[SB1]

Case 1

Case 2

Case 3

Case 4

Cancer

No

No

No

No

Skin Disorder

No

No

Yes, Psoriasis

No

Hypertension

Yes

Yes

Yes

Yes

Myocardial Infarction

No

No

No

No

Renal Failure

No

No

No

No

Diabetes

Yes

No

Yes

No

Prior CVA/TIA*

No

No

No

No

Prior DVT**

No

No

No

No

Prior Pulmonary Embolism

No

No

No

No

Immunocompromised

No

No

No

No

Vasculitis

No

No

No

No

Autoimmune Disorder

No

No

No

No

Immune Modulating Drugs

No

No

No

No

TABLE 3: Medical History.
*CVA/TIA = cerebrovascular disease/transient ischemic attack
** DVT = deep vein thrombosis

COVID-19
Cutaneous

Case 1

Case 2

Case 3

Case 4

Left leg bruise followed by skin coming off. Denied

Dry, flaky, red

Redness and burning along

any trauma to the area. Looks like left shoulder prior

skin breakout on

the forehead, scalp, ears,

to skin coming off. Pimple like spots on the chest.

the forehead and

neck. Took ibuprofen last

Another area of skin sloughing in left axilla that hadn’t

cheeks. Burns

night, rash was then worse

been noticed previously.

but doesn’t itch.

in the morning.

No

Yes, Psoriasis

No

Symptoms
Self-described

Red dots

changes

on both

immediately
surrounding

ankles
first

COVID-19

noticed by

diagnosis

his wife.

What skin
conditions
suffered from
previously

No

worsened since
COVID-19
diagnosis?

TABLE 4: Cutaneous Symptoms.

Case 1
A 51-year-old male presented to the Emergency Department due to shortness of breath, requiring oxygen
supplementation. The patient was subsequently diagnosed with COVID-19 after testing positive for the
disease by PCR. He had no previously diagnosed skin conditions to his knowledge. Upon examination, he
had a petechial rash along the bilateral feet (Figure 1) and lower extremities up to the knee (Figures 2-3). Of
note, he had not noticed the lesions himself until his wife mentioned them to him. Due to staffing
shortages, the patient stayed in the Emergency Department overnight while awaiting an inpatient room. The
images of the reported skin changes were taken the following day. The patient reported significant
improvement in the lesions since presentation, which was confirmed by the physician’s physical exam. After
presentation to the ED, non-invasive ventilation was initiated due to hypercapnia. Over the course of one
night, the patient’s respiratory symptoms improved and the patient then continued supplemental oxygen
with a nasal cannula until shortly before discharge.
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FIGURE 1: Petechiae Along the Dorsal Surfaces of the Feet and Anterior
Ankles.
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FIGURE 2: Petechiae Along the Right Anterior Pretibial Surface.
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FIGURE 3: Petechiae Along the Left Anterior Pretibial Surface.

Case 2
A 52-year-old female presented to the Emergency Department (ED) due to overall weakness and
dizziness. She stated that she had not been able to function as well over the previous two days. The patient
tested positive for COVID-19 by PCR. She did not require oxygen supplementation but did require
supportive care. At the time of the interview, the patient had been admitted for inpatient care. The patient
stated that she had two different lesions, one along the left thigh that had arisen over the past day. It first
appeared as a purple spot that then darkened, and “bubbled,” at which point the top layer of skin came
(Figure 4). There was another lesion on the left shoulder that had the appearance of the first lesion before
the skin “sloughing” (Figure 5). There was an additional ecchymotic lesion that had the appearance of the
other two lesions in the first stage of their evolution on the left axilla (Figure 6). She denied having any
recent trauma or previously diagnosed skin conditions. In addition to the lesions above she also stated that
there were small spots on her chest, appearing vesicular, that had arisen after the onset of COVID-19
symptoms (Figure 7). No additional treatment was administered for the patient’s skin lesions.
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FIGURE 4: Well-Defined Ecchymosis With Centrally Denuded Epidermis
on the Left Lateral Thigh.

FIGURE 5: Well-Defined Ecchymosis on the Left Shoulder.
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FIGURE 6: Violaceous Purpuric Patch With Hazy Borders on the Left
Axilla.

FIGURE 7: Multiple Pustules and Erythema-Tous Papules on the Chest.

Case 3
A 44-year-old male presented to the Emergency Department due to weakness, fatigue, intractable vomiting,
and anorexia. For over a week, he had been experiencing these symptoms but had worsened over the last
three days, which was why he sought medical care. The patient tested positive for COVID-19 by PCR. With
normal saline fluid resuscitation and treatment with antiemetics, his symptoms improved over two days. He
was found to have worsening erythematous plaques with greasy scales along the forehead, and bilateral
malar regions that had appeared in the past week with the onset of his illness (Figures 8-9). He denied
itchiness but stated that the lesions burned. In addition to these lesions, he had erythematous plaques with
silver scales along the bilateral elbows and knees and the left pretibial region (Figures 10-11). Although he
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stated that he had never been diagnosed with a skin condition by a physician, these lesions appeared to be
consistent with plaque psoriasis. According to the patient, these lesions had worsened significantly since the
onset of COVID-19 symptoms. He was prescribed betamethasone diproprionate cream, and over the course
of the next two days, the treatment improved his lesions.

FIGURE 8: Erythematous Patches With Greasy Scale Along the
Melolabial Folds.
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FIGURE 9: Erythematous Patch With Greasy Scale Along the Melolabial
Fold and Medial Cheek.
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FIGURE 10: Large Erythematous, Pruritic, Plaque With Silvery Scale
Along the Left Pretibial Area.
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FIGURE 11: Erythematous, Pruritic Plaques With Silvery Scale Along the
Right Knee.

Case 4
A 47-year-old female presented to the emergency department due to fever, fatigue, myalgia, shortness of
breath, and overall concern for COVID-19. The patient tested positive for COVID-19 by PCR. On exam, she
was found to have erythematous patches along the forehead and right post-auricular region (Figure 12). She
stated that the lesions had developed since the onset of COVID-19 symptoms and complained of a burning
sensation. Of note, she did admit to ingesting ibuprofen the night before presentation. The lesions were
present before ingesting ibuprofen but had worsened overnight. She had never experienced a reaction to the
drug in the past. She was not hypoxic as judged by an oxygen saturation greater than 92% and thus had no
oxygen supplementation. She was considered to be stable and discharged home from the ED.
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FIGURE 12: Multiple Pruritic Wheals.

Discussion
This study reemphasizes the array of COVID-19-induced cutaneous manifestations that can be seen in a
healthcare setting. Earlier studies have examined the number of different presentations of COVID-19 on the
skin that have arisen since the onset of the pandemic [3,4,7,20]. The cutaneous manifestations that have
been reported in this study are mainly in line with other large-scale studies regarding cutaneous
manifestations of COVID-19, including urticaria, petechia, purpura, and vesicular rashes [3,4,7,20]. Most
subjects infected with COVID-19 who reported skin changes experienced mild disease overall and
experienced no further complications [3]. This study enforces these findings as none of the subjects listed
experienced serious COVID-19 complications or required intubation with ventilator support. Only one of
the subjects in this study needed supplemental oxygen. Over three days the subject improved and was
discharged home without further complications. This patient did suffer from a vascular type rash, petechia,
which has been associated with worse outcomes in another study [2]. Subjectively, three out of four patients
rated their illness as at least 8 in COVID-19 symptoms severity. All patients reported fatigue, and three
patients reported either myalgia or fever. Only two of the patients reported having had at least one dose of
COVID-19 vaccination, regardless of manufacturer. All four patients reported a history of hypertension, and
two reported a history of diabetes.
Demographically, the subjects in this study are similar to those diagnosed by PCR in another more extensive
literature review, including in age, which had a mean of 48 years, compared to 44 years reported by Freeman
et al. and 49 years reported by Zhao et al [3,4]. Similar to a majority of other patients reporting skin findings,
patients in this study all experienced cutaneous manifestations following symptoms of COVID-19, rather
than skin findings being the first indication of COVID-19 [3]. Also of note is the vaccination status of the
patients in this study. Two were vaccinated against COVID-19, one of the two fully vaccinated, and both
received different vaccination types. There have been reactions to vaccination for COVID-19 manifested on
the skin and the appearance of autoimmune disease [21]. Notably, some of the reaction types are similar to
cutaneous changes seen during active COVID-19, which raises questions regarding pathophysiological
mechanisms, including molecular mimicry through viral proteins [21].
In addition to these more common presentations, we did note the appearance of seborrheic dermatitis that
worsened over the patient’s course of COVID-19 illness. The patient referenced in Case 3 had never
experienced lesions like this in the past, and their appearance occurred after the development of COVID-19
symptoms. A case similar to this, with new-onset seborrheic dermatitis during COVID-19 has been recorded
in a case study previously [22]. There were some differences in this case, notably, the condition of the
subject was more critical than the subject reported in this case [22]. Nevertheless, the similarities are
consistent in the sense of developing a new skin condition after the onset of COVID-19 [22]. The clinician
must be aware of the concomitant development of skin conditions, such as seborrheic dermatitis with
COVID-19, so that they can be treated appropriately and further monitored for further development of the
condition after recovery.
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There have also been instances of worsening pre-existing conditions, such as psoriasis, with the
development of COVID-19 symptoms [17,18]. One case study reported psoriatic plaques present for an
extended period. However, the lesions had acutely worsened with the development of COVID-19. Also
noteworthy, the patient has never undergone treatment for the plaques or was taking any
medications. Another case report suggests the patient’s psoriasis worsened due to hydroxychloroquine used
to treat the patient’s COVID-19 [23]. The patient presented in this study supports the findings of Ozaras et
al., considering the patient was abstinent from medications and had worsening psoriatic lesions in the
setting of COVID-19 [17].
There are very few recommendations from the American Academy of Dermatology (AAD) regarding COVID19 and cutaneous manifestations [24]. Clinical guidance resources published by the AAD ranged from
personal protective equipment (PPE) and medical supplies, office management, and management of
immune-modulating therapeutics [25]. The most recent 'Statement on Dermatologic Manifestations of
COVID-19' by the AAD urges evaluation of a single type of lesion, pernio or chilblains, and does not
elaborate on other lesions seen during the infection [26]. Even though the AAD has not been involved
extensively in creating significant guidelines regarding skin lesions during COVID-19, there have been
tremendous efforts to log the vast array of lesions being seen globally through a central database created by
the organization [3]. With this information, the medical community has attempted to better understand the
prognostic value of specific skin lesions during COVID-19 [3,27].
In addition to new lesions, it will be essential to monitor for worsening skin conditions diagnosed before
COVID-19 infection, such as the case of worsening psoriasis [17]. Treatment recommendations regarding
COVID-19 and cutaneous symptoms are often based upon targeted therapeutic approaches [8]. It should also
be noted that some lesions may require treatment with corticosteroids, which is recommended in some
cases of COVID-19 [8]. A prophylactic approach to COVID-19 might also include supplementation with
Vitamin D, which has been shown to reduce the severity of COVID-19 as well as many skin conditions
[28,29].

Conclusions
This study aims to further build upon our current understanding of COVID-19 and the presentation of the
disease through the skin. In addition to more common cutaneous manifestations of COVID-19, new-onset
and worsening of other skin conditions during the infection are described in this series. The study also builds
awareness of the effects of COVID-19 on patients who have previously diagnosed skin conditions and how
the clinician might manage worsening conditions during the illness and after recovery. The clinician should
also be aware of the skin conditions that are more likely associated with mild courses of COVID-19, such as
urticaria, and those more likely to be associated with more severe disease, such as petechia or retiform
purpura. Awareness of clinical manifestations of COVID-19 is vital for the clinician to reassure patients
presenting to them regarding the prognosis of the disease and offer supportive care if the lesions affect the
quality of life. There were limitations to this study, including the patient population, being only those who
presented to the hospital setting. There is also the possibility that there is recall bias or limitation in recall
amongst the subjects. Many of the COVID-19 cases with cutaneous manifestations are mild and only present
in an outpatient clinic. In addition, there may have been some reporter bias as the patients with more
significant and bothersome skin lesions made the physician aware that they had appeared with the onset of
COVID-19.
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